2 results
Approved WMORecruiting
The primary objective will be evaluating the difference in detection of new AF between the intervention practices (yearly 7 days AF screening with continuous heart rhythm monitoring) and control practices (care as usual) over three years of follow-…
Approved WMORecruiting
Primary:To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-5890 when used as monotherapy and in combination with pembrolizumab in the dose escalation and confirmation phase and the dose…